Analyzing Biotricity (OTCMKTS:BTCY) and 111 (NASDAQ:YI)

Biotricity (OTCMKTS:BTCY) and 111 (NASDAQ:YI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, earnings, risk and analyst recommendations.

Profitability

This table compares Biotricity and 111’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-30.02%	N/A	-75.50%
111	-0.52%	N/A	-2.70%

Risk and Volatility

Biotricity has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, 111 has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.

Valuation and Earnings

This table compares Biotricity and 111″s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	0.64	-$8.42 million	($0.17)	-1.62
111	$13.58 billion	0.00	-$1.42 million	($0.84)	-3.67

111 has higher revenue and earnings than Biotricity. 111 is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 21.3% of 111 shares are owned by institutional investors. 10.1% of Biotricity shares are owned by insiders. Comparatively, 43.9% of 111 shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Biotricity and 111, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	0	0	0	0.00
111	1	0	0	0	1.00

Summary

111 beats Biotricity on 7 of the 11 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.